

X-PACT Is Now Immunolight Cancer Therapy

A groundbreaking cancer treatment, currently in clinical trial and formerly known as X-PACT, has been rebranded as Immunolight Cancer Therapy (ICT).



DURHAM, NC, USA, August 14, 2024

/EINPresswire.com/ -- We are thrilled to announce a significant milestone in our ongoing mission to provide advanced and effective treatments for cancer patients. Our groundbreaking cancer treatment, currently in clinical trial and formerly known as X-PACT, has been rebranded as [Immunolight Cancer Therapy \(ICT\)](#).

This new name reflects an unwavering commitment to light-based innovation in cancer treatment. ICT represents a new era in oncological care, emphasizing our dedication to harnessing the power of light to advance cancer therapies.

[Immunolight](#) Cancer Therapy continues to embody the pioneering spirit that has driven our research and development efforts. This evolution in our brand identity underscores our commitment to providing patients with cutting-edge treatments that are both effective and life-changing.

For more information about Immunolight Cancer Therapy and our ongoing initiatives, please visit immunolight.com.

About Immunolight, LLC

Founded in 2007, Immunolight's mission is to innovate advancements in energy conversion technologies that create value in medicine, commercial industries, and the life sciences. Immunolight has developed a breakthrough platform technology that leverages the latest advances in energy conversion. The technology is centered on energy conversion from one part of the electromagnetic spectrum to another and the paradigm-shifting applications in a variety of medical and non-medical commercial fields. Immunolight's highest priority is to translate innovations in energy conversion, the company's core technology, to fulfill a high, unmet medical need in the development of new possibilities for targeted therapies to treat cancer, particularly through its Immunolight Cancer Treatment (formerly X-PACT).

###

Harold Walder, President

Immunolight

hwalder[at]immunolight.com

Visit us on social media:

[Facebook](#)

[Instagram](#)

[LinkedIn](#)

[X](#)

[YouTube](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/735507779>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our [Editorial Guidelines](#) for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.